

Global Biosimilar Insulin Glargine Market Growth 2023-2029

<https://marketpublishers.com/r/GAA2632E521BEN.html>

Date: March 2023

Pages: 92

Price: US\$ 3,660.00 (Single User License)

ID: GAA2632E521BEN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

Insulin glargine is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours. Insulin glargine is indicated for the treatment of diabetes mellitus in adults, adolescents and children aged two years and above.

LPI (LP Information)' newest research report, the "Biosimilar Insulin Glargine Industry Forecast" looks at past sales and reviews total world Biosimilar Insulin Glargine sales in 2022, providing a comprehensive analysis by region and market sector of projected Biosimilar Insulin Glargine sales for 2023 through 2029. With Biosimilar Insulin Glargine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Biosimilar Insulin Glargine industry.

This Insight Report provides a comprehensive analysis of the global Biosimilar Insulin Glargine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Biosimilar Insulin Glargine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Biosimilar Insulin Glargine market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Biosimilar Insulin Glargine and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of

opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Biosimilar Insulin Glargine.

The global Biosimilar Insulin Glargine market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Biosimilar Insulin Glargine is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Biosimilar Insulin Glargine is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Biosimilar Insulin Glargine is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Biosimilar Insulin Glargine players cover Eli Lilly, Gan&Lee, Tonghua Dongbao, United Laboratory, Geropharm, Biocon and Wockhardt, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar Insulin Glargine market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Pre-filled

Cartridge

Segmentation by application

Hospital

Retail Pharmacy

Others

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Eli Lilly

Gan&Lee

Tonghua Dongbao

United Laboratory

Geropharm

Biocon

Wockhardt

Key Questions Addressed in this Report

What is the 10-year outlook for the global Biosimilar Insulin Glargine market?

What factors are driving Biosimilar Insulin Glargine market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Biosimilar Insulin Glargine market opportunities vary by end market size?

How does Biosimilar Insulin Glargine break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

- 2.1 World Market Overview
 - 2.1.1 Global Biosimilar Insulin Glargine Annual Sales 2018-2029
 - 2.1.2 World Current & Future Analysis for Biosimilar Insulin Glargine by Geographic Region, 2018, 2022 & 2029
 - 2.1.3 World Current & Future Analysis for Biosimilar Insulin Glargine by Country/Region, 2018, 2022 & 2029
- 2.2 Biosimilar Insulin Glargine Segment by Type
 - 2.2.1 Pre-filled
 - 2.2.2 Cartridge
- 2.3 Biosimilar Insulin Glargine Sales by Type
 - 2.3.1 Global Biosimilar Insulin Glargine Sales Market Share by Type (2018-2023)
 - 2.3.2 Global Biosimilar Insulin Glargine Revenue and Market Share by Type (2018-2023)
 - 2.3.3 Global Biosimilar Insulin Glargine Sale Price by Type (2018-2023)
- 2.4 Biosimilar Insulin Glargine Segment by Application
 - 2.4.1 Hospital
 - 2.4.2 Retail Pharmacy
 - 2.4.3 Others
- 2.5 Biosimilar Insulin Glargine Sales by Application
 - 2.5.1 Global Biosimilar Insulin Glargine Sale Market Share by Application (2018-2023)
 - 2.5.2 Global Biosimilar Insulin Glargine Revenue and Market Share by Application (2018-2023)
 - 2.5.3 Global Biosimilar Insulin Glargine Sale Price by Application (2018-2023)

3 GLOBAL BIOSIMILAR INSULIN GLARGINE BY COMPANY

3.1 Global Biosimilar Insulin Glargine Breakdown Data by Company

3.1.1 Global Biosimilar Insulin Glargine Annual Sales by Company (2018-2023)

3.1.2 Global Biosimilar Insulin Glargine Sales Market Share by Company (2018-2023)

3.2 Global Biosimilar Insulin Glargine Annual Revenue by Company (2018-2023)

3.2.1 Global Biosimilar Insulin Glargine Revenue by Company (2018-2023)

3.2.2 Global Biosimilar Insulin Glargine Revenue Market Share by Company (2018-2023)

3.3 Global Biosimilar Insulin Glargine Sale Price by Company

3.4 Key Manufacturers Biosimilar Insulin Glargine Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Biosimilar Insulin Glargine Product Location Distribution

3.4.2 Players Biosimilar Insulin Glargine Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR BIOSIMILAR INSULIN GLARGINE BY GEOGRAPHIC REGION

4.1 World Historic Biosimilar Insulin Glargine Market Size by Geographic Region (2018-2023)

4.1.1 Global Biosimilar Insulin Glargine Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Biosimilar Insulin Glargine Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Biosimilar Insulin Glargine Market Size by Country/Region (2018-2023)

4.2.1 Global Biosimilar Insulin Glargine Annual Sales by Country/Region (2018-2023)

4.2.2 Global Biosimilar Insulin Glargine Annual Revenue by Country/Region (2018-2023)

4.3 Americas Biosimilar Insulin Glargine Sales Growth

4.4 APAC Biosimilar Insulin Glargine Sales Growth

4.5 Europe Biosimilar Insulin Glargine Sales Growth

4.6 Middle East & Africa Biosimilar Insulin Glargine Sales Growth

5 AMERICAS

5.1 Americas Biosimilar Insulin Glargine Sales by Country

5.1.1 Americas Biosimilar Insulin Glargine Sales by Country (2018-2023)

5.1.2 Americas Biosimilar Insulin Glargine Revenue by Country (2018-2023)

5.2 Americas Biosimilar Insulin Glargine Sales by Type

5.3 Americas Biosimilar Insulin Glargine Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Biosimilar Insulin Glargine Sales by Region

6.1.1 APAC Biosimilar Insulin Glargine Sales by Region (2018-2023)

6.1.2 APAC Biosimilar Insulin Glargine Revenue by Region (2018-2023)

6.2 APAC Biosimilar Insulin Glargine Sales by Type

6.3 APAC Biosimilar Insulin Glargine Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Biosimilar Insulin Glargine by Country

7.1.1 Europe Biosimilar Insulin Glargine Sales by Country (2018-2023)

7.1.2 Europe Biosimilar Insulin Glargine Revenue by Country (2018-2023)

7.2 Europe Biosimilar Insulin Glargine Sales by Type

7.3 Europe Biosimilar Insulin Glargine Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Biosimilar Insulin Glargine by Country

8.1.1 Middle East & Africa Biosimilar Insulin Glargine Sales by Country (2018-2023)

8.1.2 Middle East & Africa Biosimilar Insulin Glargine Revenue by Country (2018-2023)

8.2 Middle East & Africa Biosimilar Insulin Glargine Sales by Type

8.3 Middle East & Africa Biosimilar Insulin Glargine Sales by Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Biosimilar Insulin Glargine

10.3 Manufacturing Process Analysis of Biosimilar Insulin Glargine

10.4 Industry Chain Structure of Biosimilar Insulin Glargine

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Biosimilar Insulin Glargine Distributors

11.3 Biosimilar Insulin Glargine Customer

12 WORLD FORECAST REVIEW FOR BIOSIMILAR INSULIN GLARGINE BY GEOGRAPHIC REGION

- 12.1 Global Biosimilar Insulin Glargine Market Size Forecast by Region
 - 12.1.1 Global Biosimilar Insulin Glargine Forecast by Region (2024-2029)
 - 12.1.2 Global Biosimilar Insulin Glargine Annual Revenue Forecast by Region (2024-2029)
- 12.2 Americas Forecast by Country
- 12.3 APAC Forecast by Region
- 12.4 Europe Forecast by Country
- 12.5 Middle East & Africa Forecast by Country
- 12.6 Global Biosimilar Insulin Glargine Forecast by Type
- 12.7 Global Biosimilar Insulin Glargine Forecast by Application

13 KEY PLAYERS ANALYSIS

- 13.1 Eli Lilly
 - 13.1.1 Eli Lilly Company Information
 - 13.1.2 Eli Lilly Biosimilar Insulin Glargine Product Portfolios and Specifications
 - 13.1.3 Eli Lilly Biosimilar Insulin Glargine Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.1.4 Eli Lilly Main Business Overview
 - 13.1.5 Eli Lilly Latest Developments
- 13.2 Gan&Lee
 - 13.2.1 Gan&Lee Company Information
 - 13.2.2 Gan&Lee Biosimilar Insulin Glargine Product Portfolios and Specifications
 - 13.2.3 Gan&Lee Biosimilar Insulin Glargine Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.2.4 Gan&Lee Main Business Overview
 - 13.2.5 Gan&Lee Latest Developments
- 13.3 Tonghua Dongbao
 - 13.3.1 Tonghua Dongbao Company Information
 - 13.3.2 Tonghua Dongbao Biosimilar Insulin Glargine Product Portfolios and Specifications
 - 13.3.3 Tonghua Dongbao Biosimilar Insulin Glargine Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.3.4 Tonghua Dongbao Main Business Overview
 - 13.3.5 Tonghua Dongbao Latest Developments
- 13.4 United Laboratory
 - 13.4.1 United Laboratory Company Information
 - 13.4.2 United Laboratory Biosimilar Insulin Glargine Product Portfolios and Specifications

13.4.3 United Laboratory Biosimilar Insulin Glargine Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 United Laboratory Main Business Overview

13.4.5 United Laboratory Latest Developments

13.5 Geropharm

13.5.1 Geropharm Company Information

13.5.2 Geropharm Biosimilar Insulin Glargine Product Portfolios and Specifications

13.5.3 Geropharm Biosimilar Insulin Glargine Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 Geropharm Main Business Overview

13.5.5 Geropharm Latest Developments

13.6 Biocon

13.6.1 Biocon Company Information

13.6.2 Biocon Biosimilar Insulin Glargine Product Portfolios and Specifications

13.6.3 Biocon Biosimilar Insulin Glargine Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 Biocon Main Business Overview

13.6.5 Biocon Latest Developments

13.7 Wockhardt

13.7.1 Wockhardt Company Information

13.7.2 Wockhardt Biosimilar Insulin Glargine Product Portfolios and Specifications

13.7.3 Wockhardt Biosimilar Insulin Glargine Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 Wockhardt Main Business Overview

13.7.5 Wockhardt Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Biosimilar Insulin Glargine Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Biosimilar Insulin Glargine Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Pre-filled

Table 4. Major Players of Cartridge

Table 5. Global Biosimilar Insulin Glargine Sales by Type (2018-2023) & (K Units)

Table 6. Global Biosimilar Insulin Glargine Sales Market Share by Type (2018-2023)

Table 7. Global Biosimilar Insulin Glargine Revenue by Type (2018-2023) & (\$ million)

Table 8. Global Biosimilar Insulin Glargine Revenue Market Share by Type (2018-2023)

Table 9. Global Biosimilar Insulin Glargine Sale Price by Type (2018-2023) & (US\$/Unit)

Table 10. Global Biosimilar Insulin Glargine Sales by Application (2018-2023) & (K Units)

Table 11. Global Biosimilar Insulin Glargine Sales Market Share by Application (2018-2023)

Table 12. Global Biosimilar Insulin Glargine Revenue by Application (2018-2023)

Table 13. Global Biosimilar Insulin Glargine Revenue Market Share by Application (2018-2023)

Table 14. Global Biosimilar Insulin Glargine Sale Price by Application (2018-2023) & (US\$/Unit)

Table 15. Global Biosimilar Insulin Glargine Sales by Company (2018-2023) & (K Units)

Table 16. Global Biosimilar Insulin Glargine Sales Market Share by Company (2018-2023)

Table 17. Global Biosimilar Insulin Glargine Revenue by Company (2018-2023) (\$ Millions)

Table 18. Global Biosimilar Insulin Glargine Revenue Market Share by Company (2018-2023)

Table 19. Global Biosimilar Insulin Glargine Sale Price by Company (2018-2023) & (US\$/Unit)

Table 20. Key Manufacturers Biosimilar Insulin Glargine Producing Area Distribution and Sales Area

Table 21. Players Biosimilar Insulin Glargine Products Offered

Table 22. Biosimilar Insulin Glargine Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 23. New Products and Potential Entrants

Table 24. Mergers & Acquisitions, Expansion

Table 25. Global Biosimilar Insulin Glargine Sales by Geographic Region (2018-2023) & (K Units)

Table 26. Global Biosimilar Insulin Glargine Sales Market Share Geographic Region (2018-2023)

Table 27. Global Biosimilar Insulin Glargine Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 28. Global Biosimilar Insulin Glargine Revenue Market Share by Geographic Region (2018-2023)

Table 29. Global Biosimilar Insulin Glargine Sales by Country/Region (2018-2023) & (K Units)

Table 30. Global Biosimilar Insulin Glargine Sales Market Share by Country/Region (2018-2023)

Table 31. Global Biosimilar Insulin Glargine Revenue by Country/Region (2018-2023) & (\$ millions)

Table 32. Global Biosimilar Insulin Glargine Revenue Market Share by Country/Region (2018-2023)

Table 33. Americas Biosimilar Insulin Glargine Sales by Country (2018-2023) & (K Units)

Table 34. Americas Biosimilar Insulin Glargine Sales Market Share by Country (2018-2023)

Table 35. Americas Biosimilar Insulin Glargine Revenue by Country (2018-2023) & (\$ Millions)

Table 36. Americas Biosimilar Insulin Glargine Revenue Market Share by Country (2018-2023)

Table 37. Americas Biosimilar Insulin Glargine Sales by Type (2018-2023) & (K Units)

Table 38. Americas Biosimilar Insulin Glargine Sales by Application (2018-2023) & (K Units)

Table 39. APAC Biosimilar Insulin Glargine Sales by Region (2018-2023) & (K Units)

Table 40. APAC Biosimilar Insulin Glargine Sales Market Share by Region (2018-2023)

Table 41. APAC Biosimilar Insulin Glargine Revenue by Region (2018-2023) & (\$ Millions)

Table 42. APAC Biosimilar Insulin Glargine Revenue Market Share by Region (2018-2023)

Table 43. APAC Biosimilar Insulin Glargine Sales by Type (2018-2023) & (K Units)

Table 44. APAC Biosimilar Insulin Glargine Sales by Application (2018-2023) & (K Units)

Table 45. Europe Biosimilar Insulin Glargine Sales by Country (2018-2023) & (K Units)

Table 46. Europe Biosimilar Insulin Glargine Sales Market Share by Country

(2018-2023)

Table 47. Europe Biosimilar Insulin Glargine Revenue by Country (2018-2023) & (\$ Millions)

Table 48. Europe Biosimilar Insulin Glargine Revenue Market Share by Country (2018-2023)

Table 49. Europe Biosimilar Insulin Glargine Sales by Type (2018-2023) & (K Units)

Table 50. Europe Biosimilar Insulin Glargine Sales by Application (2018-2023) & (K Units)

Table 51. Middle East & Africa Biosimilar Insulin Glargine Sales by Country (2018-2023) & (K Units)

Table 52. Middle East & Africa Biosimilar Insulin Glargine Sales Market Share by Country (2018-2023)

Table 53. Middle East & Africa Biosimilar Insulin Glargine Revenue by Country (2018-2023) & (\$ Millions)

Table 54. Middle East & Africa Biosimilar Insulin Glargine Revenue Market Share by Country (2018-2023)

Table 55. Middle East & Africa Biosimilar Insulin Glargine Sales by Type (2018-2023) & (K Units)

Table 56. Middle East & Africa Biosimilar Insulin Glargine Sales by Application (2018-2023) & (K Units)

Table 57. Key Market Drivers & Growth Opportunities of Biosimilar Insulin Glargine

Table 58. Key Market Challenges & Risks of Biosimilar Insulin Glargine

Table 59. Key Industry Trends of Biosimilar Insulin Glargine

Table 60. Biosimilar Insulin Glargine Raw Material

Table 61. Key Suppliers of Raw Materials

Table 62. Biosimilar Insulin Glargine Distributors List

Table 63. Biosimilar Insulin Glargine Customer List

Table 64. Global Biosimilar Insulin Glargine Sales Forecast by Region (2024-2029) & (K Units)

Table 65. Global Biosimilar Insulin Glargine Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 66. Americas Biosimilar Insulin Glargine Sales Forecast by Country (2024-2029) & (K Units)

Table 67. Americas Biosimilar Insulin Glargine Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 68. APAC Biosimilar Insulin Glargine Sales Forecast by Region (2024-2029) & (K Units)

Table 69. APAC Biosimilar Insulin Glargine Revenue Forecast by Region (2024-2029) & (\$ millions)

Table 70. Europe Biosimilar Insulin Glargine Sales Forecast by Country (2024-2029) & (K Units)

Table 71. Europe Biosimilar Insulin Glargine Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 72. Middle East & Africa Biosimilar Insulin Glargine Sales Forecast by Country (2024-2029) & (K Units)

Table 73. Middle East & Africa Biosimilar Insulin Glargine Revenue Forecast by Country (2024-2029) & (\$ millions)

Table 74. Global Biosimilar Insulin Glargine Sales Forecast by Type (2024-2029) & (K Units)

Table 75. Global Biosimilar Insulin Glargine Revenue Forecast by Type (2024-2029) & (\$ Millions)

Table 76. Global Biosimilar Insulin Glargine Sales Forecast by Application (2024-2029) & (K Units)

Table 77. Global Biosimilar Insulin Glargine Revenue Forecast by Application (2024-2029) & (\$ Millions)

Table 78. Eli Lilly Basic Information, Biosimilar Insulin Glargine Manufacturing Base, Sales Area and Its Competitors

Table 79. Eli Lilly Biosimilar Insulin Glargine Product Portfolios and Specifications

Table 80. Eli Lilly Biosimilar Insulin Glargine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 81. Eli Lilly Main Business

Table 82. Eli Lilly Latest Developments

Table 83. Gan&Lee Basic Information, Biosimilar Insulin Glargine Manufacturing Base, Sales Area and Its Competitors

Table 84. Gan&Lee Biosimilar Insulin Glargine Product Portfolios and Specifications

Table 85. Gan&Lee Biosimilar Insulin Glargine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 86. Gan&Lee Main Business

Table 87. Gan&Lee Latest Developments

Table 88. Tonghua Dongbao Basic Information, Biosimilar Insulin Glargine Manufacturing Base, Sales Area and Its Competitors

Table 89. Tonghua Dongbao Biosimilar Insulin Glargine Product Portfolios and Specifications

Table 90. Tonghua Dongbao Biosimilar Insulin Glargine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 91. Tonghua Dongbao Main Business

Table 92. Tonghua Dongbao Latest Developments

Table 93. United Laboratory Basic Information, Biosimilar Insulin Glargine

Manufacturing Base, Sales Area and Its Competitors

Table 94. United Laboratory Biosimilar Insulin Glargine Product Portfolios and Specifications

Table 95. United Laboratory Biosimilar Insulin Glargine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 96. United Laboratory Main Business

Table 97. United Laboratory Latest Developments

Table 98. Geropharm Basic Information, Biosimilar Insulin Glargine Manufacturing Base, Sales Area and Its Competitors

Table 99. Geropharm Biosimilar Insulin Glargine Product Portfolios and Specifications

Table 100. Geropharm Biosimilar Insulin Glargine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 101. Geropharm Main Business

Table 102. Geropharm Latest Developments

Table 103. Biocon Basic Information, Biosimilar Insulin Glargine Manufacturing Base, Sales Area and Its Competitors

Table 104. Biocon Biosimilar Insulin Glargine Product Portfolios and Specifications

Table 105. Biocon Biosimilar Insulin Glargine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 106. Biocon Main Business

Table 107. Biocon Latest Developments

Table 108. Wockhardt Basic Information, Biosimilar Insulin Glargine Manufacturing Base, Sales Area and Its Competitors

Table 109. Wockhardt Biosimilar Insulin Glargine Product Portfolios and Specifications

Table 110. Wockhardt Biosimilar Insulin Glargine Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 111. Wockhardt Main Business

Table 112. Wockhardt Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Biosimilar Insulin Glargine
- Figure 2. Biosimilar Insulin Glargine Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Biosimilar Insulin Glargine Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Biosimilar Insulin Glargine Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Biosimilar Insulin Glargine Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Pre-filled
- Figure 10. Product Picture of Cartridge
- Figure 11. Global Biosimilar Insulin Glargine Sales Market Share by Type in 2022
- Figure 12. Global Biosimilar Insulin Glargine Revenue Market Share by Type (2018-2023)
- Figure 13. Biosimilar Insulin Glargine Consumed in Hospital
- Figure 14. Global Biosimilar Insulin Glargine Market: Hospital (2018-2023) & (K Units)
- Figure 15. Biosimilar Insulin Glargine Consumed in Retail Pharmacy
- Figure 16. Global Biosimilar Insulin Glargine Market: Retail Pharmacy (2018-2023) & (K Units)
- Figure 17. Biosimilar Insulin Glargine Consumed in Others
- Figure 18. Global Biosimilar Insulin Glargine Market: Others (2018-2023) & (K Units)
- Figure 19. Global Biosimilar Insulin Glargine Sales Market Share by Application (2022)
- Figure 20. Global Biosimilar Insulin Glargine Revenue Market Share by Application in 2022
- Figure 21. Biosimilar Insulin Glargine Sales Market by Company in 2022 (K Units)
- Figure 22. Global Biosimilar Insulin Glargine Sales Market Share by Company in 2022
- Figure 23. Biosimilar Insulin Glargine Revenue Market by Company in 2022 (\$ Million)
- Figure 24. Global Biosimilar Insulin Glargine Revenue Market Share by Company in 2022
- Figure 25. Global Biosimilar Insulin Glargine Sales Market Share by Geographic Region (2018-2023)
- Figure 26. Global Biosimilar Insulin Glargine Revenue Market Share by Geographic Region in 2022
- Figure 27. Americas Biosimilar Insulin Glargine Sales 2018-2023 (K Units)
- Figure 28. Americas Biosimilar Insulin Glargine Revenue 2018-2023 (\$ Millions)

- Figure 29. APAC Biosimilar Insulin Glargine Sales 2018-2023 (K Units)
- Figure 30. APAC Biosimilar Insulin Glargine Revenue 2018-2023 (\$ Millions)
- Figure 31. Europe Biosimilar Insulin Glargine Sales 2018-2023 (K Units)
- Figure 32. Europe Biosimilar Insulin Glargine Revenue 2018-2023 (\$ Millions)
- Figure 33. Middle East & Africa Biosimilar Insulin Glargine Sales 2018-2023 (K Units)
- Figure 34. Middle East & Africa Biosimilar Insulin Glargine Revenue 2018-2023 (\$ Millions)
- Figure 35. Americas Biosimilar Insulin Glargine Sales Market Share by Country in 2022
- Figure 36. Americas Biosimilar Insulin Glargine Revenue Market Share by Country in 2022
- Figure 37. Americas Biosimilar Insulin Glargine Sales Market Share by Type (2018-2023)
- Figure 38. Americas Biosimilar Insulin Glargine Sales Market Share by Application (2018-2023)
- Figure 39. United States Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)
- Figure 40. Canada Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)
- Figure 41. Mexico Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)
- Figure 42. Brazil Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)
- Figure 43. APAC Biosimilar Insulin Glargine Sales Market Share by Region in 2022
- Figure 44. APAC Biosimilar Insulin Glargine Revenue Market Share by Regions in 2022
- Figure 45. APAC Biosimilar Insulin Glargine Sales Market Share by Type (2018-2023)
- Figure 46. APAC Biosimilar Insulin Glargine Sales Market Share by Application (2018-2023)
- Figure 47. China Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)
- Figure 48. Japan Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)
- Figure 49. South Korea Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)
- Figure 50. Southeast Asia Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)
- Figure 51. India Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)
- Figure 52. Australia Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)
- Figure 53. China Taiwan Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)
- Figure 54. Europe Biosimilar Insulin Glargine Sales Market Share by Country in 2022
- Figure 55. Europe Biosimilar Insulin Glargine Revenue Market Share by Country in 2022
- Figure 56. Europe Biosimilar Insulin Glargine Sales Market Share by Type (2018-2023)
- Figure 57. Europe Biosimilar Insulin Glargine Sales Market Share by Application

(2018-2023)

Figure 58. Germany Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)

Figure 59. France Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)

Figure 60. UK Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)

Figure 61. Italy Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)

Figure 62. Russia Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)

Figure 63. Middle East & Africa Biosimilar Insulin Glargine Sales Market Share by Country in 2022

Figure 64. Middle East & Africa Biosimilar Insulin Glargine Revenue Market Share by Country in 2022

Figure 65. Middle East & Africa Biosimilar Insulin Glargine Sales Market Share by Type (2018-2023)

Figure 66. Middle East & Africa Biosimilar Insulin Glargine Sales Market Share by Application (2018-2023)

Figure 67. Egypt Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)

Figure 68. South Africa Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)

Figure 69. Israel Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)

Figure 70. Turkey Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)

Figure 71. GCC Country Biosimilar Insulin Glargine Revenue Growth 2018-2023 (\$ Millions)

Figure 72. Manufacturing Cost Structure Analysis of Biosimilar Insulin Glargine in 2022

Figure 73. Manufacturing Process Analysis of Biosimilar Insulin Glargine

Figure 74. Industry Chain Structure of Biosimilar Insulin Glargine

Figure 75. Channels of Distribution

Figure 76. Global Biosimilar Insulin Glargine Sales Market Forecast by Region (2024-2029)

Figure 77. Global Biosimilar Insulin Glargine Revenue Market Share Forecast by Region (2024-2029)

Figure 78. Global Biosimilar Insulin Glargine Sales Market Share Forecast by Type (2024-2029)

Figure 79. Global Biosimilar Insulin Glargine Revenue Market Share Forecast by Type (2024-2029)

Figure 80. Global Biosimilar Insulin Glargine Sales Market Share Forecast by Application (2024-2029)

Figure 81. Global Biosimilar Insulin Glargine Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Biosimilar Insulin Glargine Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/GAA2632E521BEN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GAA2632E521BEN.html>